We are pleased to announce Dr. @KotechaMD as a speaker at VIRO 2026 – Global Voices in Renal Oncology.

Dr. Kotecha is Assistant Attending Physician in the Genitourinary Oncology and Cellular Therapy Service at @MSKCancerCenter, United States. His clinical and research interests munotherapy, and novel cellular therapy approaches for renal cell carcinoma.

His expertise in kidney cancer, immunotherapy, and innovative cellular therapies will bring valuable perspective to this international discussion on contemporary kidney cancer management.

🔗 Register here: oncodaily.com/viro-registrat…

Additional faculty announcements will follow soon.

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors.

Now, a new form of highly sensitive CAR T cells aims to overcome one of the biggest barriers in solid tumor immunotherapies—the way solid tumors lack a single, widely
By engineering an ultra-sensitive receptor capable of detecting even the smallest amounts of the protein CD70, researchers report in Science they were able to eradicate kidney, ovarian, and pancreatic tumors in preclinical models.

The findings provide a potential strategy to treat a broad range of solid tumors. scim.ag/400e2WU

🧵 How do older patients actually do with dual IO for mccRCC?

Presenting at #ASCOGU2026 a joint @MSKCancerCenter + @MDAndersonnews collaboration–the largest reported real-world cohort of patients treated with 1L ipilimumab/nivolumab (>500 pts).

Here's what we learned ⬇️

Cellular therapy development in RCC has lagged behind other tumor types. Novel CAR-T and BiTE approaches are starting to gain traction with initial clinical activity signals. Further development and large-scale trials are needed.

On behalf of a terrific team of investigators (@BGarmezy @KotechaMD @DrKarieRuncie @BraunMDPhD et al), very proud to present the 1st data for XmAb819, a first-in-class ENPP3 x CD3 bispecific in patients with #kidneycancer. We have long needed new targets beyond #VEGF-axis & checyou are at the @AACR @theNCI @EORTC #Targets25, come visit our poster in the session starting at noon today - if not, read below ... (1/8)

🔍 2pm at #KCRS25: Trials in Progress led by @motzermd - packed w updates you won’t want to miss:

@NazliDizman IVORY
@KotechaMD ENPP3 x CD3
@BradMcG04 STRIKE
@PrafulRavi1 LASER
@DrKarieRuncie EXACT
@VincentWenxinXu NK cell immune therapy

Plenty to discuss!

New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use. bit.ly/40W306e

Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. journals.lww.com/immunotherapy-… @nirmishsingla @montypal @KotechaMD @MattZibelman

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors buff.ly/3UON4PS

A new article from our group with @KotechaMD and led by Lennert Eismann + Amy Xie reports that investigational RNA biomarkers in RCC (and likely other diseases) are sensitive to tissue source site (i.e. whether they are obtained from primary or met tissue) sciencedirect.com/science/articl…

📣Dr. Rupesh Kotecha, chief of radiosurgery, has been invited to present with the Middle Eastern Society for Stereotactic and Functional Neurosurgery at their first-ever Stereotactic Radiosurgery Webinar.

@RrKotecha will be discussing the current state of modern #SRS platforms. Congratulations Dr. Kotecha!

Learn more: forms.gle/cNdsg95CjJn3m4…

Thank you @KidneyCancer for this tremendous & humbling opportunity to help advance the field of research for patients affected by kidney cancer! Incredibly grateful for support of my mentors & collaborators at @WilmotCancer & @MSKCancerCenter that made the proposal possible @ChungHanLee3 @KotechaMD @IyerGopa Dr Van Veldhuizen

(1/n) Our latest work in @EurUrolFocus bit.ly/3YxpWnL is a retrospective study from @MSKCancerCenter and @MDAndersonNews reporting outcomes with ICT by CN status in patients with sarcomatoid and/or rhabdoid dediff @PavlosMsaouel @arihakimi @KotechaMD

Genetic ancestry and molecular correlations in patients with #KidneyCancer. Presentation by @KotechaMD @MSKCancerCenter. #IKCSNA22 written coverage by @MikeLattanzi @TexasOncology > bit.ly/3h3y53l @KidneyCancer

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations

buff.ly/3Uf2NoX

@ChungHanLee3 @KotechaMD @Dr_Aggen @DrNeilJShah @DrDarrenFeldman @motzermd

Last #KCRS22 tweet: @KotechaMD and I went to @MidlandPS ‘s Dow High years ago. Now, as a GU #geneticcounselor and #oncologist , conference run ins have become a norm. Mr. Koski (our AP Bio teacher) would be so proud. #michiganstrong

New work on SDH-/FH-deficient RCC from our @MSKCancerCenter Kidney Cancer Team, driven by (newly matched!) med student Angela Yoo, Cerise Tang, and Mark Zucker. Thanks @arihakimi @KotechaMD, all collaborators, and of course the patients who contributed sciencedirect.com/science/articl…

We are part of this outstanding Academy of Kidney Cancer Investigators @BraunMDPhD @AChakrabortyPhD @KotechaMD Amrita Mangalvedhekar and Krishnendu Pal. Thank you for your leadership and guidance @brian_rini